Table 1. Standard patient cohort demographics (N=829).
| Patient demographics (N=829) | Mortality <30 days | Mortality >30 days | P value |
|---|---|---|---|
| Age (SD) | 55.9 (9.3) yrs | 55.9 (8.7) yrs | 0.98 |
| Gender | 0.004 | ||
| Male | 126 (86.9%) | 519 (75.8%) | |
| Female | 19 (13.1%) | 165 (24.1%) | |
| Race | 0.463 | ||
| Caucasian | 48 (33.1%) | 199 (29.1%) | |
| African-American | 49 (33.7%) | 210 (30.7%) | |
| Hispanic | 34 (23.4%) | 193 (28.2%) | |
| Asian | 14 (9.7%) | 82 (12%) | |
| HBV | 0.940 | ||
| Positive | 23 (15.9%) | 111 (16.2%) | |
| Negative | 110 (75.9%) | 541 (79%) | |
| HCV | 0.918 | ||
| Positive | 96 (66.2%) | 457 (70.1%) | |
| Negative | 43 (29.7%) | 209 (30.6%) | |
| AFP (SD) | 80,597.01 (182,220.9) | 15,241.62 (77,195.21) | <0.0001 |
| Total bilirubin (SD) | 5.48 (6.83) | 1.99 (2.95) | <0.0001 |
| INR (SD) | 1.67 (0.75) | 1.34 (0.7) | <0.0001 |
| Albumin (SD) | 2.34 (0.68) | 2.85 (0.71) | <0.0001 |
| AST (SD) | 331.4 (342.6) | 153.8 (295.7) | <0.0001 |
| Platelets (SD) | 193.5 (127.3) | 181.7 (129.3) | 0.33 |
| Creatinine (SD) | 1.43 (1.03) | 0.97 (0.48) | <0.0001 |
| APRI (SD) | 6.38 (7.22) | 3.52 (9.75) | 0.002 |
| MELD (SD) | 19.0 (8.2) | 11.7 (4.5) | <0.0001 |
| Stage | <0.0001 | ||
| I | 9 (6.2%) | 143 (20.9%) | |
| II | 11 (7.6%) | 125 (18.3%) | |
| III | 38 (26.2%) | 182 (26.6%) | |
| IV | 75 (51.7%) | 200 (29.2%) | |
| Unknown | 12 (8.3%) | 33 (4.8%) | |
| Treatment | <0.0001 | ||
| Yes | 12 (8.3%) | 364 (53.2%) | |
| No | 122 (84.1%) | 283 (41.4%) | |
| Surgery | 0.011 | ||
| Yes | 4 (2.8%) | 63 (9.2%) | |
| No | 130 (89.7%) | 581 (84.9%) | |
| Chemotherapy | <0.0001 | ||
| Yes | 5 (3.4%) | 204 (29.8%) | |
| No | 129 (89%) | 440 (64.3%) | |
| Radiotherapy | 0.065 | ||
| Yes | 1 (0.7%) | 25 (3.7%) | |
| No | 133 (91.7%) | 616 (90.1%) |
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; INR, international normalized ratio; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; MELD, model for end stage liver disease.